Author: Michelle Dryden

Categories
Culture Healthcare Lifestyle Perks Science Technology

Oticon celebrates winners of the Annual Oticon Focus on People Awards

12 inspiring individuals recognized for empowering and advocating for people with hearing loss

 

SOMERSET, N.J. — (BUSINESS WIRE) — #FOP — Oticon, Inc. announced the winners of the 2022 Oticon Focus on People Awards, a national program dedicated to honoring outstanding individuals who have made a positive impact on the hearing loss community. Thousands of people from around the world voted during Fall 2022 to determine this year’s winners in four categories.

 

The 2022 first place winners are:

  • Student: Erin Cembrale of Dunedin, Florida views her hearing loss as a strength that motivates her to try harder and never give up. This commitment has fueled a successful soccer career. Since age 3, Erin has played for a variety of club, high school and college teams, including the U.S. Deaf Women’s National Team (USDWNT), with whom she won gold in the 2022 Deaflympics in Brazil. This year, she will travel to Korea with the USDWNT to compete in the World Cup. Off the field, Erin inspires and mentors young soccer players with disabilities.
  • Adult: Zina Jawadi of Los Altos Hills, California is an advocate for people with hearing loss among medical professionals. She believes accommodations are essential in establishing trust, formulating a diagnosis, creating an effective treatment plan, and ensuring patients play an active role in their health. A medical student herself, Zina is the youngest ever member of the Hearing Loss Association of America’s Board of Directors. Her long-term goal is to increase representation of people with hearing loss in medicine and to address accessibility barriers for people with hearing loss and with disabilities more broadly. Zina plans to donate all prizes, including the hearing aids, from this award to the Hearing Loss Association of America.
  • Advocacy: Gregory Scott of New York, New York drew on his personal experiences with hearing loss to create SoundPrint, a crowdsourcing app that enables anyone to measure and report the sound levels in bars and restaurants. SoundPrint serves as an important free resource for people with and without hearing loss who are looking for quieter venues that make conversation easier. Additionally, the SoundPrint database is shared with venue managers, public health researchers, and hearing health advocates to let them know people care about noise.
  • Practitioner: Jamie Marotto of Fairfield, Connecticut is the Director of the Sacred Heart University (SHU) Undergraduate Program in Communication Disorders and Director of the Audiology Clinic. She knows the value of integrating classroom teachings with clinical experience, especially when caring for patients in underserved communities. In the clinic, students learn how evaluating and treating hearing loss across a lifespan can improve a patient’s ability to work, interact socially and minimize health risks associated with hearing loss. To further drive home the importance of using their knowledge and skills to give back, Dr. Marotto leads students on an annual service-learning trip to Guatemala to provide hearing-related services and hearing aid fittings to in-need children and adults.

 

“From the youngest students to accomplished professionals and global brands, the winners of this year’s Oticon Focus on People Awards are redefining perceptions of hearing loss, encouraging inclusivity, and empowering others around them,” said Nancy Palmere Mucha, Director of Consumer Marketing and Public Relations for Oticon, Inc. “Through their leadership, advocacy, and resilience, they are inspiring change and making the world a better place for people with hearing loss.”

 

As part of this year’s program, Oticon has also recognized Barbie with Hearing Aids and leading toy manufacturer Mattel with a special award for the brand’s commitment to creating dolls with a variety of looks to represent everyone. The brand unveiled Barbie with Hearing Aids in 2022 as part of their ongoing efforts to amplify diversity and inclusion.

 

“The Barbie brand believes in the power of representation, and we are committed to continuing to introduce dolls, like Barbie with Hearing Aids, that reflect the diversity children see in the world around them,” said Lisa McKnight, Executive Vice President and Global Head of Barbie and Dolls, Mattel. “It’s important for young people to see themselves reflected in our products. And it’s equally important to encourage children to play with dolls that may not resemble them to help them understand and celebrate the importance of inclusion.”

 

The 2022 Oticon Focus on People Award winners were revealed on February 25 during the Oticon Next Conference, a gathering of hearing care professionals from around the country. As part of the event, Mattel donated more than 950 Barbie with Hearing Aids dolls to the hearing care professionals in attendance, equipping them with a valuable tool to connect with patients.

 

Established in 1997, the Oticon Focus on People Awards program has honored more than 300 outstanding individuals throughout the United States. This year’s second and third place winners are:

  • Student — Lauren Harris of Knoxville, Tennessee; Mercy Botchway of Everett, Massachusetts
  • Adult — Meaghan Thomas of Nashville, Tennessee; Shirley Forpe of Palatine, Illinois
  • Advocacy — Renee Polanco Lucerno of Culver City, California; Shanna Groves of Olathe, Kansas
  • Practitioner — Dawn Heiman of Woodridge, Illinois; Mary Frintner of Burbank, California

 

First place winners received a $1,000 prize as well as a $1,000 donation from Oticon to the non-profit organization of their choice. In addition, first place winners in the Student, Adult, and Advocacy categories received a pair of Oticon hearing aids.

 

To read the stories of all the Oticon Focus on People Awards finalists, visit Oticon.com/FOP.

Photos and videos from each of the 2022 Oticon Focus on People Award winners are available here.

 

Oticon, Inc. – Life-Changing Technology

Oticon is one of the world’s most innovative hearing device manufacturers, with more than 115 years’ experience in the design and development of hearing aids for adults and children. Our comprehensive portfolio of life-changing technology improves not only the quality of hearing but the overall quality of life for people with hearing loss. Oticon challenges conventions and pushes the limits of technology to bring to market hearing solutions that exceed the needs and expectations of people with hearing loss, so that they can live their lives without limit. Our groundbreaking BrainHearing™ technology is helping to provide better hearing with less effort by giving the brain the clearest, purest sound signals to decode. For more information visit oticon.com.

Contacts

Media
Allie Carroll

Gregory FCA

alliec@gregoryfca.com
267-294-7735

Categories
Culture Education Sports & Gaming

AM Best names four finalists in Student Challenge competition

OLDWICK, N.J. — (BUSINESS WIRE) — AM Best has selected students from the University of Wisconsin and Florida State University as finalists for its third annual Student Challenge competition, which tasked entrants with creating solutions for managing insurance risks. The 2023 competition was open to undergraduate and graduate students, who were invited to submit as individuals or in teams.

Chris Lane and Madison Wescott of the University of Wisconsin were selected for their submission, “TikTok as a Penetration Tool for Insurance,” which couples the pervasiveness of the quickly growing social media app with insurance awareness for younger audiences.

 

Siddarth Upadhya and Rail Minazetdinov from the same university earned their spot amongst the finalists for their submission, “Resilience Bonds for Risk Mitigation in the Energy Sector.” Their proposed resilience bond would support investment in the industry and resilient infrastructure, thereby mitigating commodity price risk by removing carbon-based energy sources.

 

Kevin Taheri and David Leemon, another team from the University of Wisconsin, have made it to the final round with their proposal, “New Framework to Assess the Risk and Underwriting for Autonomous Vehicles.” Taheri and Leemon’s proposed framework would assess the risk, underwrite the policy and set prices of autonomous vehicles alongside manufacturers.

 

Finally, Hannah Youngblood from Florida State University was selected for her submission, “Telemedicine Platform for Prescriptions.” Her proposed platform would perform a comparative analysis of a consumer’s prescriptions based on their insurance coverage and suggest the most cost-effective solution.

 

Final presentations will be posted on the Student Challenge website for viewing and voting Wednesday, March 23, through Monday, April 10. Finalists will be notified of the results via email on Tuesday, April 18, and the winner will be published in Best’s Review® Thursday, June 1.

 

“Our annual Student Challenge connects with one of AM Best’s core values: to innovate the insurance industry by tapping into the next generation of professionals,” said Lee McDonald, group vice president of AM Best Information Services. “It’s a pleasure to see the creative solutions these students come up with each year.”

 

AM Best’s 2023 Student Challenge is one of the company’s ongoing initiatives to support the development of new talent in the insurance industry. It is sponsored by the AM Best Foundation, which supports charitable organizations that encourage education and thought leadership in insurance and risk management. AM Best also provides an analytical development program for college students, along with internship opportunities. For more information about the competition, please visit our website.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Lee McDonald
Group Vice President
AM Best – Information Services
+1 908 439 2200, ext. 5561
lee.mcdonald@ambest.com

Categories
Business Perks

Cherry Hill Mortgage Investment Corporation announces fourth quarter and full year 2022 results

FARMINGDALE, N.J. — (BUSINESS WIRE) — Cherry Hill Mortgage Investment Corporation (NYSE: CHMI) “(Cherry Hill” or the “Company)” reported results for the fourth quarter and full year 2022 Tuesday.

 

Fourth Quarter 2022 Highlights

  • GAAP net loss applicable to common stockholders of $34.5 million, or $1.59 per share
  • Earnings available for distribution (“EAD”) attributable to common stockholders of $5.3 million, or $0.24 per share
  • Common book value per share of $6.06 at December 31, 2022
  • Declared regular common dividend of $0.27 per share, annualized common dividend yield at market close was 16.2% on March 6, 2023
  • Aggregate portfolio leverage stood at 3.8x at December 31, 2022
  • As of December 31, 2022, the Company had unrestricted cash of $57.3 million

 

“Our efforts to protect book value the past few quarters have been effective,” said Jay Lown, President and Chief Executive Officer of Cherry Hill Mortgage Investment Corporation. “Looking forward, we believe we remain thoughtfully leveraged given the challenging macro environment and will continue to be opportunistic in deploying capital in 2023.”

 

Operating Results

Cherry Hill reported GAAP net loss applicable to common stockholders for the fourth quarter of 2022 of $34.5 million, or $1.59 per diluted weighted average common share outstanding. Reported GAAP net loss was determined based primarily on the following: $1.4 million of net interest income, $10.4 million of net servicing income, a net realized loss of $30.7 million on RMBS, a net realized gain of $8.5 million on derivatives, a net unrealized loss of $13.5 million on derivatives, a net unrealized loss of $7.2 million on Servicing Related Assets, and general administrative expenses and management fee paid to Cherry Hill’s external manager in the aggregate amount of $3.2 million.

 

Earnings available for distribution attributable to common stockholders for the fourth quarter of 2022 were $5.3 million, or $0.24 per basic and diluted weighted average common share outstanding. For a reconciliation of GAAP net income to non-GAAP earnings available for distribution, please refer to the reconciliation table accompanying this release.

 

Three Months Ended
December 31, 2022 September 30, 2022
(unaudited) (unaudited)
Income
Interest income $

9,906

$

8,213

Interest expense

8,539

4,882

Net interest income

1,367

3,331

Servicing fee income

13,700

13,426

Servicing costs

3,304

2,725

Net servicing income

10,396

10,701

Other income (loss)
Realized loss on RMBS, available-for-sale, net

(30,701

)

(9,735

)
Realized gain on derivatives, net

8,521

6,210

Unrealized gain (loss) on derivatives, net

(13,526

)

33,321

Unrealized gain (loss) on investments in Servicing Related Assets

(7,198

)

2,293

Total Income (Loss)

(31,141

)

46,121

Expenses
General and administrative expense

1,587

1,475

Management fee to affiliate

1,597

1,625

Total Expenses

3,184

3,100

Income (Loss) Before Income Taxes

(34,325

)

43,021

Provision for (Benefit from) corporate business taxes

(1,572

)

1,344

Net Income (Loss)

(32,753

)

41,677

Net (income) loss allocated to noncontrolling interests in Operating Partnership

702

(866

)
Dividends on preferred stock

2,463

2,462

Net Income (Loss) Applicable to Common Stockholders $

(34,514

)

 $

38,349

Net Income (Loss) Per Share of Common Stock
Basic $

(1.59

)

 $

1.91

Diluted $

(1.59

)

 $

1.90

Weighted Average Number of Shares of Common Stock Outstanding
Basic

21,648,846

20,123,165

Diluted

21,682,287

20,156,606

_______________

Dollar amounts in thousands, except per share amounts.

Net unrealized gain on the Company’s RMBS portfolio for the fourth quarter 2022 was approximately $41.7 million.

 

Three Months Ended
December 31, 2022 September 30, 2022
(unaudited) (unaudited)
Net Income (Loss) $

(32,753

)

 $

41,677

Other comprehensive income (loss):
Unrealized gain (loss) on RMBS, available-for-sale, net

41,655

(46,592

)
Net other comprehensive income (loss)

41,655

(46,592

)
Comprehensive income (loss) $

8,902

$

(4,915

)
Comprehensive income (loss) attributable to noncontrolling interests in Operating Partnership

197

(92

)
Dividends on preferred stock

2,463

2,462

Comprehensive income (loss) attributable to common stockholders $

6,242

$

(7,285

)

______________

Dollar amounts in thousands.

Portfolio Highlights for the Quarter Ended December 31, 2022

The Company realized net servicing fee income of $10.4 million and net interest income of $1.4 million, offset by other loss of $42.9 million, primarily related to realized losses on RMBS, as well as unrealized losses on derivatives and investments in Servicing Related Assets. The unpaid principal balance for the MSR portfolio stood at $21.7 billion as of December 31, 2022 and the carrying value of the MSR portfolio ended the quarter at $279.7 million. Net interest spread for the RMBS portfolio stood at 3.77% and the debt-to-equity ratio on the aggregate portfolio ended the quarter at 3.8x.

 

The RMBS portfolio had a book value of approximately $960 million and carrying value of approximately $931 million at quarter-end December 31, 2022. The portfolio had a weighted average coupon of 4.23% and weighted average maturity of 29 years.

 

In order to mitigate duration risk and interest rate risk associated with the Company’s RMBS and MSRs, Cherry Hill used interest rate swaps, TBAs Treasury futures and options on Treasury futures. At quarter end December 31, 2022, the Company held interest rate swaps with a notional amount of $1.3 billion, TBAs with a notional amount of ($306.1) million, Treasury futures with a notional amount of ($88.7) million and options on Treasury futures with a notional amount of $20.0 million.

 

As of December 31, 2022, Cherry Hill’s GAAP book value was $6.06 per diluted share, net of the fourth quarter dividend.

 

Dividends

On December 16, 2022, the Board of Directors declared a quarterly dividend of $0.27 per share of common stock for the fourth quarter of 2022. The dividend was paid in cash on January 31, 2023 to common stockholders of record as of the close of business on December 30, 2022. Additionally, Cherry Hill announced that its Board of Directors declared a dividend of $0.5125 per share on the Company’s 8.20% Series A Cumulative Redeemable Preferred Stock and $0.515625 per share on the Company’s 8.250% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock for the fourth quarter 2022. The dividends were paid in cash on January 17, 2023 to Series A and B Preferred stockholders of record as of the close of business on December 30, 2022.

 

Earnings Available for Distribution

Earnings available for distribution (“EAD”) is a non-GAAP financial measure that the Company defines as GAAP net income (loss), excluding realized gain (loss) on RMBS, realized and unrealized gain (loss) on derivatives, realized gain (loss) on acquired assets, realized and unrealized gain (loss) on investments in MSRs (net of any estimated MSR amortization) and any tax (benefit) expense on realized and unrealized gain (loss) on MSRs. MSR amortization refers to the portion of the change in fair value of the MSR that is primarily due to the realization of cashflows, runoff resulting from prepayments and an adjustment for any gain or loss on the capital used to purchase the MSR. EAD also includes interest rate swap periodic interest income (expense) and drop income on TBA dollar roll transactions, which are included in “Realized loss on derivatives, net” on the consolidated statements of income (loss). EAD is adjusted to exclude outstanding LTIP-OP Units in the Company’s Operating Partnership and dividends paid on the Company’s preferred stock.

 

EAD is provided for purposes of potential comparability to other issuers that invest in residential mortgage-related assets. The Company believes providing investors with EAD, in addition to related GAAP financial measures, may provide investors some insight into the Company’s ongoing operational performance. However, the concept of EAD does have significant limitations, including the exclusion of realized and unrealized gains (losses), and given the apparent lack of a consistent methodology among issuers for defining EAD, it may not be comparable to similarly titled measures of other issuers, which define EAD differently from us and each other. As a result, EAD should not be considered a substitute for the Company’s GAAP net income (loss) or as a measure of the Company’s liquidity. While EAD is one indicia of the Company’s earnings capacity, it is not the only factor considered in setting a dividend and is not the same as REIT taxable income which is calculated in accordance with the rules of the IRS.

 

The following table provides a reconciliation of net income to EAD for the three months ended December 31, 2022 and September 30, 2022:

 

Three Months Ended
December 31, 2022 September 30, 2022
(unaudited) (unaudited)
Net Income (Loss) $

(32,753

)

 $

41,677

Realized loss on RMBS, net

30,701

9,735

Realized gain on derivatives, net ¹

(2,180

)

(2,143

)
Unrealized loss (gain) on derivatives, net

13,526

(33,321

)
Unrealized gain on investments in MSRs, net of estimated MSR amortization

(1,206

)

(10,590

)
Tax (benefit) expense on realized and unrealized (loss) gain on MSRs

(217

)

2,404

Total EAD: $

7,871

$

7,762

EAD attributable to noncontrolling interests in Operating Partnership

(143

)

(153

)
Dividends on preferred stock

2,463

2,462

EAD Attributable to Common Stockholders $

5,265

$

5,147

EAD Attributable to Common Stockholders, per Diluted Share $

0.24

$

0.26

GAAP Net Income (Loss) Per Share of Common Stock, per Diluted Share $

(1.59

)

 $

1.90

_________

Dollar amounts in thousands, except per share amounts.

  1. Excludes drop income on TBA dollar rolls of $0.7 million and interest rate swap periodic interest income of $5.6 million for the three-month period ended December 31, 2022. Excludes drop income on TBA dollar rolls of $0.8 million and interest rate swap periodic interest income of $3.2 million for the three-month period ended September 30, 2022.

Additional Information

Additional information regarding Cherry Hill’s financial condition and results of operations can be found in its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 7, 2023. In addition, an investor presentation with supplemental information regarding Cherry Hill, its business and its financial condition as of December 31, 2022 and its results of operations for the full year 2022 has been posted to the Investor Relations section of Cherry Hill’s website, www.chmireit.com. Cherry Hill will discuss the investor presentation on the conference call referenced below.

 

Fourth Quarter 2022 Earnings Release and Conference Call

The Company’s management will host a conference call today at 5:00 pm Eastern Time. A copy of this earnings release and the investor presentation referenced above will be posted to the Investor Relations section of Cherry Hill’s website, www.chmireit.com. All interested parties are welcome to participate on the live call.

 

A live webcast of the conference call will be available in the investor relations section of the Company’s website at www.chmireit.com. To listen to the live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download and install any necessary audio software. An online archive of the webcast will be available on the Company’s website for 1 year following the call.

 

Participants may register for the conference call here. Once registered, dial-in information for the call will be made available.

 

About Cherry Hill Mortgage Investment Corporation

Cherry Hill Mortgage Investment Corporation is a real estate finance company that acquires, invests in and manages residential mortgage assets in the United States. For additional information, visit www.chmireit.com.

 

Forward-Looking Statements

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including, among others, statements relating to the Company’s long-term growth opportunities and strategies, expand its market opportunities and create its own Excess MSRs and its ability to generate sustainable and attractive risk-adjusted returns for stockholders. These forward-looking statements are based upon the Company’s present expectations, but these statements are not guaranteed to occur. For a description of factors that may cause the Company’s actual results or performance to differ from its forward-looking statements, please review the information under the heading “Risk Factors” included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and other documents filed by the Company with the Securities and Exchange Commission.

Contacts

Investor Relations

(877) 870 –7005

InvestorRelations@CHMIreit.com

Categories
Business

AM Best withdraws Credit Rating of State Auto Financial Corporation

OLDWICK, N.J. — (BUSINESS WIRE) — #insurance — AM Best has affirmed the Long-Term Issuer Credit Rating of “bbb” (Good) of State Auto Financial Corporation (State Auto) (Columbus, OH). The outlook of this Credit Rating (rating) is stable. AM Best has withdrawn the rating as the company has requested to no longer participate in AM Best’s interactive rating process.

 

The ratings affirmation reflects State Auto’s status as a downstream holding company in the Liberty Mutual hierarchy, though currently there is no debt maintained at this entity.

 

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments.

 

AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

 

Copyright © 2023 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

Raymond Thomson, CPCU, ARe, ARM
Associate Director
+1 908 439 2200, ext. 5621
raymond.thomson@ambest.com

Christopher Sharkey
Manager, Public Relations
+1 908 439 2200, ext. 5159
christopher.sharkey@ambest.com

Michael Lagomarsino, CFA, FRM
Senior Director
+1 908 439 2200, ext. 5810
michael.lagomarsino@ambest.com

Al Slavin
Senior Public Relations Specialist
+1 908 439 2200, ext. 5098
al.slavin@ambest.com

Categories
Business Lifestyle Technology Travel & Leisure

Herley joins CAES, strengthening position as advanced RF company

ARLINGTON, Va. — (BUSINESS WIRE) — #RF — CAES, a leading provider of mission-critical advanced RF technology, is pleased to announce that Herley has joined CAES, further expanding the company’s footprint in the RF market. The combination positions CAES to deliver even greater capabilities and specialized knowledge across RF, and develop the best solutions for tomorrow’s missions.


Herley delivers high-integrity, small Size, Weight and Power (SWaP) and application specific RF and electronic warfare assemblies, tactical RF products and missile flight instrumentation solutions. With facilities in Woburn, Massachusetts; Whippany, New Jersey; and Lancaster, Pennsylvania, the company brings an experienced team, strong customer relationships and new strategic programs to CAES.

 

“Being a partner of choice for our customers and helping to solve their toughest advanced RF problems is our top priority,” said Mike Kahn, president and CEO, CAES. “We’re excited to welcome the Herley team to CAES as they share this focus. Combining our specialized knowledge will only continue to strengthen our work to build strong partnerships, deliver quality products and better serve our industry.”

 

Both CAES and Herley provide solutions for the world’s toughest missions. Herley excels at designing and manufacturing microwave electronic products and solutions for the aerospace and defense industries, aligning with CAES’ leadership and extensive experience in the industry. With the combination, CAES grows its portfolio of solutions with added capabilities in missile flight instrumentation, customized RF solutions for microwave assemblies and tactical radio frequency.

 

“As we start this next chapter with CAES, we’re excited about the alignment of our product offerings and strategic goals,” said Bill Fejes, president Specialist Radio Frequency, Herley. “Together, we look forward to creating new opportunities for both our customers and our employees.”

 

About CAES

CAES is a pioneer of advanced electronics for the most challenging defense and aerospace trusted systems. As a leading provider of advanced RF technology to the United States aerospace and defense industry, CAES delivers high-reliability RF and digital solutions that enable our customers to ensure a safer, more secure planet. On land, at sea and in the air, CAES’ extensive experience in the RF market and enhanced manufacturing capabilities are at the forefront of mission-critical military and aerospace innovation. www.caes.com

Contacts

Alaina Monismith

CAES

alaina.monismith@caes.com

Categories
Business Culture Education

Barnes & Noble Education announces rescheduling of Third Quarter Fiscal Year 2023 Earnings Release and Conference Call

BASKING RIDGE, N.J. — (BUSINESS WIRE) — Barnes & Noble Education, Inc. (NYSE: BNED), a leading solutions provider for the education industry, today announced that the Company is rescheduling its third quarter Fiscal Year 2023 earnings report previously scheduled for Tuesday, March 7, 2023 at 8:30 a.m. Eastern Time.

 

The rescheduling allows the Company adequate time to close on its amended and extended asset-backed revolving and term loan credit facilities, which the Company expects to close on or before Thursday, March 9, 2023.

 

The Company intends to report Fiscal 2023 third quarter earnings results on Thursday, March 9, 2023, after market close. The Company will host an investor conference call at 4:30 p.m. Eastern Time on Thursday, March 9, 2023, to review the Company’s financial results and operations.

 

This call is being webcast and can be accessed at Barnes & Noble Education’s corporate website at www.bned.com. The webcast of this call will be archived and available for three months on Barnes & Noble Education’s corporate website.

 

ABOUT BARNES & NOBLE EDUCATION, INC.

Barnes & Noble Education, Inc. (NYSE: BNED) is a leading solutions provider for the education industry, driving affordability, access and achievement at hundreds of academic institutions nationwide and ensuring millions of students are equipped for success in the classroom and beyond. Through its family of brands, BNED offers campus retail services and academic solutions, a digital direct-to-student learning ecosystem, unparalleled best-in-class assortment of school apparel through a strategic alliance with Fanatics and Lids, wholesale capabilities and more. BNED is a company serving all who work to elevate their lives through education, supporting students, faculty and institutions as they make tomorrow a better, more inclusive and smarter world. For more information, visit www.bned.com.

 

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and information relating to us and our business that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used in this communication, the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will,” “forecasts,” “projections,” and similar expressions, as they relate to us or our management, identify forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make, including any statements made in regards to our response to the COVID-19 pandemic. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Such statements reflect our current views with respect to future events, the outcome of which is subject to certain risks, including, among others: risks associated with public health crises, epidemics, and pandemics, such as the COVID-19 pandemic, including the duration, spread, severity, and any recurrences thereof, and the impact such public health crises have on the overall demand for BNED products and services, our operations, the operations of our suppliers and other business partners, and the effectiveness of our response to these risks; general competitive conditions, including actions our competitors and content providers may take to grow their businesses; a decline in college enrollment or decreased funding available for students; decisions by colleges and universities to outsource their physical and/or online bookstore operations or change the operation of their bookstores; implementation of our digital strategy may not result in the expected growth in our digital sales and/or profitability; risk that digital sales growth does not exceed the rate of investment spend; the performance of our online, digital and other initiatives, integration of and deployment of, additional products and services including new digital channels, and enhancements to higher education digital products, and the inability to achieve the expected cost savings; the risk of price reduction or change in format of course materials by publishers, which could negatively impact revenues and margin; the general economic environment and consumer spending patterns; decreased consumer demand for our products, low growth or declining sales; the strategic objectives, successful integration, anticipated synergies, and/or other expected potential benefits of various acquisitions may not be fully realized or may take longer than expected; the integration of the operations of various acquisitions into our own may also increase the risk of our internal controls being found ineffective; changes to purchase or rental terms, payment terms, return policies, the discount or margin on products or other terms with our suppliers; our ability to successfully implement our strategic initiatives including our ability to identify, compete for and execute upon additional acquisitions and strategic investments; risks associated with operation or performance of MBS Textbook Exchange, LLC’s point-of-sales systems that are sold to college bookstore customers; technological changes; risks associated with counterfeit and piracy of digital and print materials; our international operations could result in additional risks; our ability to attract and retain employees; risks associated with data privacy, information security and intellectual property; trends and challenges to our business and in the locations in which we have stores; non-renewal of managed bookstore, physical and/or online store contracts and higher-than-anticipated store closings; disruptions to our information technology systems, infrastructure and data due to computer malware, viruses, hacking and phishing attacks, resulting in harm to our business and results of operations; disruption of or interference with third party web service providers and our own proprietary technology; work stoppages or increases in labor costs; possible increases in shipping rates or interruptions in shipping service; product shortages, including decreases in the used textbook inventory supply associated with the implementation of publishers’ digital offerings and direct to student textbook consignment rental programs, as well as the risks associated with the impacts that public health crises may have on the ability of our suppliers to manufacture or source products, particularly from outside of the United States; changes in domestic and international laws or regulations, including U.S. tax reform, changes in tax rates, laws and regulations, as well as related guidance; enactment of laws or changes in enforcement practices which may restrict or prohibit our use of texts, emails, interest based online advertising, recurring billing or similar marketing and sales activities; the amount of our indebtedness and ability to comply with covenants applicable to any future debt financing; our ability to satisfy future capital and liquidity requirements; our ability to access the credit and capital markets at the times and in the amounts needed and on acceptable terms; adverse results from litigation, governmental investigations, tax-related proceedings, or audits; changes in accounting standards; and the other risks and uncertainties detailed in the section titled “Risk Factors” in Part I – Item 1A in our Annual Report on Form 10-K for the year ended April 30, 2022. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results or outcomes may vary materially from those described as anticipated, believed, estimated, expected, intended or planned. Subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements in this paragraph. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Contacts

Media Contact:
Carolyn J. Brown

Senior Vice President, Chief Communications Officer

Barnes & Noble Education, Inc.

(908) 991-2967

cbrown@bned.com

Investor Contact:
Hunter Blankenbaker

Vice President, Investor Relations

Barnes & Noble Education, Inc.

(908) 991-2776

hblankenbaker@bned.com

Categories
Business Science

Merck’s investigational Activin signaling inhibitor Sotatercept improved six-minute walk distance by 40.8 meters at week 24 versus placebo in adults with pulmonary arterial hypertension on background therapy

Sotatercept demonstrated statistically significant improvements in 8 of 9 secondary measures, including reduction in risk of clinical worsening or death

Results presented today at ACC.23/WCC and published in The New England Journal of Medicine

 

RAHWAY, N.J. — (BUSINESS WIRE) — $MRK #MRK — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced full results from the Phase 3 STELLAR trial, which evaluated sotatercept, Merck’s novel investigational activin signaling inhibitor biologic, in combination with stable background therapy for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1). Sotatercept significantly improved exercise capacity, increasing 6-minute walk distance (6MWD) by 40.8 meters (95% CI, 27.5-54.1; p<0.001) from baseline at week 24, the study’s primary endpoint.

In addition, sotatercept demonstrated statistically significant and clinically meaningful improvements in eight of nine secondary outcome measures, including improvements in WHO functional class (WHO FC) and pulmonary vascular resistance (PVR). Sotatercept reduced the risk of clinical worsening or death by 84% compared to placebo with a median follow-up of 32.7 weeks (HR=0.16 [95% CI, 0.08-0.35]; p<0.001). The safety profile of sotatercept was generally consistent with that observed in previous studies with sotatercept. These data were presented today at the American College of Cardiology’s 72nd Annual Scientific Session together with World Heart Federation’s World Congress of Cardiology and simultaneously published in The New England Journal of Medicine.

 

“PAH is a rare, rapidly progressive, debilitating and ultimately life-threatening condition with a five-year mortality rate of 43 percent,” said Dr. Marius Hoeper, Hannover Medical School, Germany, and lead investigator. “Sotatercept demonstrated profound improvements across the primary endpoint of six-minute walk distance and multiple secondary endpoints, including improvements in WHO functional class and pulmonary vascular resistance. These landmark results show the potential of sotatercept and the approach of targeting cellular signaling associated with vascular hyperproliferation and pathological remodeling for the treatment of PAH.”

 

“The results from the Phase 3 STELLAR trial are immensely important to physicians and patients and highlight the critical role sotatercept may play in improving exercise capacity and other meaningful clinical outcome measures for patients with PAH,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “These findings are compelling given the profound reduction in the risk of clinical worsening or death in patients treated with sotatercept on top of background therapy. We look forward to discussing these pivotal data with health authorities and are working with urgency to bring this potential new treatment option to patients.”

 

STELLAR is the first Phase 3 study to evaluate the efficacy of an activin signaling inhibitor added to background therapy in adults with PAH. Key findings from secondary endpoints included:

  • The proportion of patients who achieved multicomponent improvement at week 24 (defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide (NT-proBNP) level, and either improvement in WHO FC or maintenance of WHO FC II) was significantly greater with sotatercept versus placebo (38.9% [n=63/163] versus 10.1% [n=16/160]; p<0.001).
  • Sotatercept demonstrated a statistically significant reduction of -234.6 dyn·sec·cm−5 (95% CI, -288.4 to -180.8; p<0.001) from baseline at week 24 in PVR – a calculation of pulmonary artery pressure, pulmonary artery wedge pressure and cardiac output – versus placebo.
  • Sotatercept demonstrated a statistically significant reduction of -441.6 (95% CI, -573.5 to -309.6; p<0.001) from baseline at week 24 in NT-proBNP levels versus placebo.
  • Patients receiving sotatercept were significantly more likely to improve and maintain WHO FC at week 24 versus placebo. 29.4% (n=48/163) of patients in the sotatercept group improved in WHO FC compared to 13.8% (n=22/160) in the placebo group (p<0.001).
  • Sotatercept significantly reduced events associated with clinical worsening (defined by death of any cause or specified non-fatal clinical worsening events). With a median follow-up of 32.7 weeks, 9 of 163 patients in the sotatercept group died or experienced a clinical worsening event versus 42 of 160 patients in the placebo group (HR=0.16 [95% CI, 0.08 to 0.35]; p<0.001).
  • A significantly greater proportion of patients treated with sotatercept achieved or maintained a low French risk score (attaining or maintaining all three low-risk criteria: WHO functional class I or II, 6-minute walk distance > 440 meters, and NT-proBNP level < 300 pg per milliliter) versus placebo (39.5% [n=64/163] versus 18.2% [n=29/160]; p<0.001).
  • In patient-reported outcomes using the PAH-SYMPACT® questionnaire, the average scores for Physical Impacts (change from baseline: -0.26 [95% CI, -0.49 to -0.04]; p=0.010) and Cardiopulmonary Symptoms (change from baseline: -0.13 [95% CI, -0.26 to -0.01]; p=0.028) were significantly reduced in patients treated with sotatercept versus placebo. PAH-SYMPACT® is a disease-specific patient-reported outcome instrument. Domain scores range from 0 to 4 with higher scores indicating greater severity of symptoms.
  • The average score for Cognitive/Emotional Impacts using PAH-SYMPACT® was not significantly different between patients treated with sotatercept versus placebo (p=0.156).

 

Treatment-emergent adverse events (TEAEs) occurred in 90.8% of patients who received sotatercept versus 91.9% of patients who received placebo, while severe TEAEs were observed in 12.9% versus 18.1% of patients, respectively. Adverse events that occurred more frequently with sotatercept versus placebo were bleeding events, telangiectasia, increased hemoglobin levels, thrombocytopenia, increased blood pressure, and dizziness.

 

Study design and additional data from the STELLAR trial

STELLAR (NCT04576988) was a pivotal Phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the safety and efficacy of sotatercept in adult patients with PAH (WHO Group 1) being treated with background therapy with WHO Functional Class (FC) II or III. The primary endpoint of the study was exercise capacity, as measured by change from baseline in week 24 6MWD. Nine secondary endpoints, tested hierarchically in the following order, were multicomponent improvement, change in PVR, NT-proBNP level, improvement in WHO FC, time to clinical worsening or death, French risk score, and the PAH-SYMPACT® Physical Impacts, Cardiopulmonary Symptoms and Cognitive/Emotional Impacts domain scores; all assessed at week 24 except clinical worsening, which was assessed when the last patient completed the week 24 visit.

 

The study enrolled a total of 323 participants who were randomized to receive either sotatercept (n=163) once every 3 weeks at a dose of 0.3 mg/kg at visit 1 and a dose of 0.7 mg/kg thereafter or placebo (n=160) added to stable background PAH therapy. The study population characteristics were: mean [±SD] 47.9 ± 14.8 years of age; 89% white; 79% female; and average length of time since PAH diagnosis of 8.8 years. In total,198 of the randomized patients (61.3%) were receiving triple therapy and 129 patients (39.9%) were receiving prostacyclin infusion therapy. Demographic and baseline characteristics were similar between the sotatercept and placebo groups.

 

The safety profile of sotatercept was generally consistent with that observed in the Phase 2 PULSAR trial. Seven patients (4.4%) in the placebo group and two patients (1.2%) in the sotatercept group died during the study through the data cutoff date.

 

About pulmonary arterial hypertension (PAH)

Pulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening blood vessel disorder characterized by the constriction of small pulmonary arteries and elevated blood pressure in the pulmonary circulation. Approximately 40,000 people in the U.S. are living with PAH. The disease progresses rapidly for many patients. PAH results in significant strain on the heart, leading to limited physical activity, heart failure and reduced life expectancy. The five-year mortality rate for patients with PAH is approximately 43%.

 

About sotatercept

Sotatercept is an investigational, potential first-in-class activin signaling inhibitor biologic being studied for the treatment of PAH (WHO Group 1). PAH is a rare disease caused, in part, by hyperproliferation of cells in the arterial walls in the lung, leading to narrowing and abnormal constriction. In pre-clinical models, sotatercept has been shown to modulate vascular cell proliferation, reversing vascular and right ventricle remodeling.

 

Sotatercept has been granted Breakthrough Therapy Designation and Orphan Drug designation by the U.S. Food and Drug Administration (FDA), as well as Priority Medicines designation and Orphan Drug designation by the European Medicines Agency for the treatment of PAH. Merck acquired exclusive rights to sotatercept in the pulmonary hypertension field through the acquisition of Acceleron Pharma Inc. Sotatercept is the subject of a licensing agreement with Bristol Myers Squibb.

 

About Merck

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

 

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Contacts

Media:

Julie Cunningham

(617) 519-6264

Ayn Wisler

(917) 691-6218

Investor:

Peter Dannenbaum

(908) 740-1037

Damini Chokshi

(908) 740-1807

Categories
Business Entertainment News Lifestyle Sports & Gaming

Lemonade Stand at Main & Vine excited to team up with Minor League Baseball ahead of 2023 Season

 New Peach Varietal to Hit Shelves Just in Time for Baseball Season

 

LIVERMORE, Calif. — (BUSINESS WIRE) — Lemonade Stand at Main & Vine is taking its trio of All-American wines out to the ballpark this summer as a proud sponsor of Minor League Baseball (MiLB). A classic twist on an American favorite, these refreshing and sweet wines – each blended with all natural flavors of freshly squeezed lemonade and ripe-picked fruit – will be available for sampling at 25 MiLB stadiums across the nation including California, Michigan, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Tennessee, and Texas. Full list of participating ballparks can be found at mainandvinewine.com/milb/.


“It’s an exciting time for Lemonade Stand and The Wine Group; not only is the Minor League Baseball sponsorship a first for the brand, but we have a new Peach Lemonade Moscato on deck that we know will be a home run,” said Kimberly Geluz, Vice President of Value Portfolio and Innovation for The Wine Group.

 

“Nothing says Americana like lemonade and baseball, so we are happy to offer a delicious take on a familiar favorite for fans to enjoy at the ballpark or at home on a warm summer evening.”

 

Peach Lemonade Moscato, the newest squeeze to join the lineup, will be available in April, and it is a refreshing infusion of delightfully sweet Moscato bursting with all natural flavors of fresh-squeezed lemonade and sun-ripened peaches with a smooth, juicy finish. Baseball fans can expect to try this new flavor at the ballpark along with the Lemonade Moscato and Strawberry Lemonade Rosé flavors which debuted last year.

 

“Minor League Baseball is proud to offer Lemonade Stand at Main & Vine at 25 ballparks this season,” says Allison Creekmore, Vice President of Minor League Baseball Business Operations at MLB.

 

“Pairing these refreshing wines with America’s national pastime not only will bring our avid fan bases together, but long-lasting memories will be created with every swing of the bat.”

 

About Lemonade Stand at Main & Vine

Lemonade Stand at Main & Vine is a new line of wines blended with natural flavors of fresh-squeezed lemonade and ripe sun-kissed fruit. The wine is now available nationally in three blends, Lemonade Moscato, Strawberry Lemonade Rosé, and new Peach Lemonade Moscato, with a suggested retail price of $7.99 for 750mL and $11.99 for 1.5L. Lemonade Stand at Main & Vine wines are lower in alcohol at 6.5% ABV and only 90 calories per 5 oz serving, as well as vegan-friendly and gluten-free. Available in 750mL and 1.5L bottles, this ready-to-drink (RTD) beverage is best enjoyed cold and served over ice.

 

Lemonade Stand at Main & Vine is a proud supporter of Alex’s Lemonade Stand Foundation for Childhood Cancer. The foundation’s mission is to change the lives of children with cancer through funding impactful research, raising awareness, supporting families, and empowering everyone to help cure childhood cancer.

 

To learn more about where to purchase Lemonade Stand at Main & Vine, visit the Main & Vine website at www.mainandvinewine.com or on social media at @LemonadeStandWines and @Mainandvinewine.

 

About The Wine Group

Established in 1981, The Wine Group is America’s second largest winery. Its portfolio of wines includes Cupcake Vineyards, Franzia, 7 Deadly, Beringer Main & Vine, Benziger Family Winery, Chloe Wine Collection, Charles Smith Wines, Cooper and Thief, The Dreaming Tree, Imagery Estate Winery, Lemonade Stand @ Main & Vine, Tribute, and numerous other brands.

 

About Minor League Baseball

Minor League Baseball (“MiLB”) consists of 120 teams across four classification levels (Single-A, High-A, Double-A and Triple-A) that are affiliated with Major League Baseball’s 30 teams. Fans flock to MiLB games to see baseball’s future stars and experience the affordable family friendly entertainment that has been a staple of MiLB since its inception in 1901. For more information, visit MiLB.com. Follow MiLB on Facebook, Instagram and Twitter.

Contacts

Press:

Holly Jefferis

hjefferis@hunterpr.com

Categories
Business Lifestyle Sports & Gaming Technology

MSG Networks provides updates on new streaming initiatives

New Direct-to-Consumer and Authenticated Streaming Product – MSG+ – to Launch this Summer; Preliminary Direct-to-Consumer Pricing Announced

New Recently Launched Free Ad-Supported Streaming TV (FAST) Channel MSG SportsZone Gains Distribution

 

NEW YORK — (BUSINESS WIRE) — MSG Networks continues to build on its history of innovation with its announcement today of new digital initiatives that will make its content available to new audiences – MSG+, a state-of-the art streaming product launching this summer that will offer access on a direct-to-consumer subscription and authenticated basis, and MSG SportsZone, a new free ad-supported streaming television (FAST) channel that will expose MSG Networks brands more widely and to audiences who are not already subscribers.

MSG+

MSG+ is being developed as a state-of-the-art streaming platform to provide fans in the region with the ability to access MSG Networks’ exclusive coverage of their favorite teams wherever they are and on their favorite devices ranging from mobile and tablet to connected TVs and other large screen applications. Fans who do not subscribe to a traditional, bundled pay television service may subscribe to MSG+ on a direct-to-consumer basis by purchasing monthly ($29.99) and annual ($309.99) subscriptions, which will include MSG Network and MSG SportsNet and all MSG-produced Knicks, Rangers, Islanders, Devils, and Sabres games as well as other live sports, events and programming included on the networks in their area. Additionally, fans will be able to purchase single games of their favorite local teams ($9.99 per game), an innovative offering not made available by any other regional sports network. MSG+ will be available at no additional charge to subscribers of participating pay television service providers of MSG Networks, replacing MSG GO as the company’s authenticated streaming service. New features including live betting odds, personalized offers and wider availability on devices will continue to add value for these bundled consumers. Additional details will be released prior to the launch this summer. In the meantime, interested fans are encouraged to visit MSG Networks’ new website – www.msgplus.tv – to register to receive updates and more information.

 

MSG SportsZone

MSG SportsZone was recently launched nationally as a free ad-supported streaming TV (FAST) channel which features a mix of original programming from MSG Networks’ content library. MSG SportsZone is currently available on Vizio and Plex with additional FAST platforms expected to come soon. A national audience will now be able to sample MSG Networks’ sports betting, classic and other original programming.

 

“MSG Networks is delighted to be able to offer fans more ways to watch our compelling and award-winning content,” said Andrea Greenberg, MSG Networks President and CEO. “The introduction of MSG+ this summer will be a significant milestone for our company and will offer a mix of subscription options for fans who do not subscribe to a traditional, bundled pay television subscription. MSG+ will also provide significant value for our participating traditional distribution partners by offering access at no additional cost to their subscribers who receive our networks. In addition, we are pleased to introduce MSG SportsZone, a new platform that expands our reach nationally and provides us additional opportunities to monetize our archive and other non-game content.”

 

Logos for MSG+ and MSG SportsZone are attached or can be found here.

 

About MSG Networks

MSG Networks, a pioneer in sports media, owns and operates two award-winning regional sports and entertainment networks and a streaming service that serve the nation’s number one media market, the New York DMA, as well as other portions of New York, New Jersey, Connecticut and Pennsylvania. The networks feature a wide range of compelling sports content, including exclusive live local games and other programming of the New York Knicks, New York Rangers, New York Islanders, New Jersey Devils and Buffalo Sabres, as well as significant coverage of the New York Giants and Buffalo Bills. This content, in addition to a diverse array of other sporting events and critically acclaimed original programming, has established MSG Networks as the gold standard in regional sports. MSG Networks is a subsidiary of Madison Square Garden Entertainment Corp. (NYSE: MSGE).

Contacts

Dan Schoenberg / 212-465-6367

Alana Udwin / 212-631-5660

Categories
Art & Life Business Education

Wiley schedules third quarter 2023 earnings release and conference call

HOBOKEN, N.J. — (BUSINESS WIRE) — Wiley (NYSE: WLY), one of the world’s largest publishers and a global leader in scientific research and career-connected education, will release its third quarter 2023 results prior to market open on Thursday, March 9, 2023. The Company has scheduled a conference call beginning at 10 am ET that day to discuss the results.

 

  • The live audio webcast and presentation slides will be available at https://events.q4inc.com/attendee/486910551, or on Wiley’s Investor Relations website at investors.wiley.com. An archive of the webcast, presentation, and transcript will be available for a period of one year.
  • US and Canada callers, please dial (888) 210-3346 and enter the participant code 2521217#. Or International callers, please dial (646) 960-0253 and enter the participant code 2521217#.

 

About Wiley

Wiley is one of the world’s largest publishers and a global leader in scientific research and career-connected education. Founded in 1807, Wiley enables discovery, powers education, and shapes workforces. Through its industry-leading content, digital platforms, and knowledge networks, the company delivers on its timeless mission to unlock human potential. Visit us at Wiley.com. Follow us on Facebook, Twitter, LinkedIn and Instagram.

Contacts

Investors:
Brian Campbell

(201) 748-6874

brian.campbell@wiley.com